Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

THE DECODER / 3/30/2026

📰 NewsSignals & Early TrendsIndustry & Market Moves

Key Points

  • Eli Lilly has signed a $2.75 billion deal with AI drug developer Insilico Medicine, signaling major investment in AI-assisted drug discovery.
  • The agreement reflects Lilly’s strategy to accelerate parts of the drug development pipeline by leveraging AI capabilities in R&D.
  • Insilico Medicine’s positioning as an AI-focused biotech is reinforced by the scale and financial commitment of the partnership.
  • The deal is a market signal that large pharma is increasingly treating AI drug development vendors as strategic collaborators rather than experimental partners.

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.

The article Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine appeared first on The Decoder.